美国发作性复发性前庭性眩晕的经济负担评估
本经济评估利用2018年MarketScan商业数据库理赔数据,识别了MD、VM和BPPV患者共53 210例及34 738例正常对照,分析其直接医疗费用。作者认为不必要的影像检查和前庭功能测试是降低费用的考虑因素,但需进一步研究和广泛教育以优化诊疗。
要点
- MD、VM和BPPV患者年度人均调整后直接费用分别为9579、11 371和8247美元。
- 作者认为不必要的影像检查和前庭功能测试是降低费用的考虑因素。
核心结论
- MD、VM和BPPV三种常见复发性眩晕原因均带来可观医疗费用,不必要的影像检查和前庭功能测试是降低费用的考虑因素,但需进一步研究和广泛教育以优化诊疗。
研究设计与样本
- 经济评估研究,使用2018年MarketScan商业数据库理赔数据,识别非Medicare的MD、VM或BPPV诊断患者,数据分析时间为2018年1月1日至12月31日。
主要发现
- 共纳入53 210例患者(平均[SD]年龄47.8[11.8]岁;67.6%女性),另有34 738例正常对照。
- 数据集中MD患者5783例(10.9%),VM患者3526例(6.6%),BPPV患者43 901例(82.5%)。
- 不同前庭疾病组间平均年龄和性别存在差异。
- 各组中无合并症或Charlson合并症指数评分为0的患者比例范围为98.4%至98.8%。
- 约5%的患者住院,住院时间持续4.6至5.2天。
临床怎么用
- 作者认为不必要的影像检查和前庭功能测试是降低费用的考虑因素。
- 作者指出需要进一步研究和广泛教育以优化前庭疾病或头晕患者的诊断、治疗和照护。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Understanding of the economic burden of recurrent vestibular causes of vertigo and areas contributing to the cost is needed. OBJECTIVE: To analyze and identify the factors contributing to the direct medical costs associated with Ménière disease (MD), vestibular migraine (VM), and benign paroxysmal positional vertigo (BPPV). DESIGN, SETTING, AND PARTICIPANTS: This economic evaluation used MarketScan Commercial Database claims data from 2018 to identify the non-Medicare patient population with the diagnoses of MD, VM, or BPPV. Data were analyzed January 1 to December 31, 2018. MAIN OUTCOMES AND MEASURES: The total direct medical costs associated with MD, VM, and BPPV. RESULTS: A total of 53 210 patients (mean [SD] age, 47.8 [11.8] years; 67.6% female) were included in this study, with 34 738 normal comparisons. There were 5783 (10.9%) patients with MD, 3526 (6.6%) patients with VM, and 43 901 (82.5%) patients with BPPV in the data set. Mean age and sex were different across the different vestibular disorders. Across the different groups, patients with no comorbidities or with a Charlson Comorbidity Index score of zero ranged from 98.4% to 98.8%. Around 5% of patients were hospitalized with inpatient stay lasting between 4.6 and 5.2 days. After adjusting for age, sex, and comorbidities, there were large differences in mean adjusted annual payments/direct costs across the different groups (MD, $9579; VM, $11 371; and BPPV, $8247). This equated to a total incremental estimated cost of $60 billion compared with the normal population. The number of outpatient brain magnetic resonance imaging or computed tomography scans per patient ranged anywhere from 1 to 20, while the number of inpatient brain magnetic resonance imaging or computed tomography scans per patient ranged anywhere from 1 to 6. A heat map of the total cost expenditure indicated that the costs were concentrated around the Midwest, Lake Michigan, and the East Coast. CONCLUSIONS AND RELEVANCE: In this economic evaluation, the 3 most common causes of recurrent vertigo-MD, VM, and BPPV-had considerable medical costs associated with them. Extraneous imaging orders and vestibular testing are factors to consider for cost reduction. However, further research and widespread education is needed to optimize the diagnosis, treatment, and care of patients presenting with vestibular disorders or dizziness.
引用
- Jeong SS, Simpson KN, Johnson JM, et al. Assessment of the Cost Burden of Episodic Recurrent Vestibular Vertigo in the US. JAMA Otolaryngol Head Neck Surg. 2022. PMID: 36227614. doi:10.1001/jamaoto.2022.3247
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。